Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alexion Pharmaceuticals Inc.

http://www.alexion.com

Latest From Alexion Pharmaceuticals Inc.

Takeda Moves Takhzyro Toward Dominant Position In Pediatric HAE

The company announced data from the Phase III SPRING study of Takhzyro in children aged 2-11; there is no approved long-term prophylactic therapy for children under 6.

Inflammation Business Strategies

Deal Watch: Iktos Doubles Its 2022 Alliance Tally In Agreements With Galapagos, Zealand

French AI-driven drug design firm will employ multiple technology platforms in latest tie-ups. Apellis looks to augment Empaveli-led portfolio in C3 complement R&D alliance with Affilogic.

Deal Watch Business Strategies

Finance Watch: Venture Floodgates Open With New Funds, Dozens Of Rounds

Private Company Edition: While the tough state of financing for publicly traded drug developers continues, venture capital firms and private biopharma companies revealed billions of dollars in new VC funds and start-up financings, including $100m-plus mega-rounds for Tessa, Alladapt and ImCheck.

Financing Innovation

Potential For Functional Cure Opens Up With GSK’s Hepatitis B Candidate

Bepirovirsen made the hepatitis B virus undetectable in nearly 30% of patients in a Phase II study – but it remains to be seen whether this response be sustained once treatment with the novel antisense product ends.

Commercial Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Alexion Pharma K.K. (formerly Legend K.K. or Legend Pharma Co., Ltd.) (Japan)
    • AstraZeneca PLC
    • Enobia Pharma Corp.
    • Portola Pharmaceuticals, Inc. (PTLA)
    • Synageva BioPharma Corp.
    • Syntimmune, Inc.
    • Taligen Therapeutics, Inc.
    • Wilson Therapeutics AB
UsernamePublicRestriction

Register